Relaxin family peptide receptor (RXFP1) coupling to Galphai3, involves the C-terminal Arg752 and localization within membrane raft microdomains

Michelle Louise Halls, Emma Therese van der Westhuizen, John D Wade, Bronwyn Anne Evans, Ross A D Bathgate, Roger James Summers

Research output: Contribution to journalArticleResearchpeer-review

20 Citations (Scopus)


The relaxin family peptide receptors (RXFP) 1 and 2 are targets for the relaxin family peptides relaxin and insulin-like peptide 3 (INSL3) respectively. Although both receptors and peptides share a high degree of sequence identity, the cAMP signaling pathways activated by the two systems are quite distinct. Relaxin activation of RXFP1 initially results in accumulation of cAMP via Galphas but this is modulated by inhibition of cAMP through GalphaoB. With time, RXFP1 recruits coupling to Galphai3 causing additional cAMP accumulation via a Galphai3-Gbetagamma-PI3K-PKCzeta pathway. In contrast, INSL3 activation of RXFP2 results in accumulation of cAMP only via Galphas, modulated by cAMP inhibition through GalphaoB. Thus the aim of this study was to identify the cause of differential G-protein coupling between these highly similar receptors. Construction of chimeric receptors revealed that Galphai3 coupling is dependent upon the transmembrane region of RXFP1 and independent of the receptor ectodomain or ligand bound. Generation of C-terminal truncated receptors identified the terminal 10 amino acids of the RXFP1 C-terminus as essential for Galphai3 signaling, and point mutations revealed an obligatory role for Arg(752). RXFP1-mediated Galphai3, but not Galphas or GalphaoB, signaling was also found to be dependent upon membrane rafts, and RXFP1 coupled to Galphai3 after only 3 min of receptor stimulation. Therefore RXFP1 coupling to the Galphai3-Gbetagamma-PI3K-PKCzeta pathway requires the terminal 10 amino acids of the RXFP1 C-terminus and membrane raft localisation, and the observed delay in this pathway occurs downstream of Galphai3.
Original languageEnglish
Pages (from-to)415 - 428
Number of pages14
JournalMolecular Pharmacology
Issue number2
Publication statusPublished - 2009

Cite this